AR044567A1 - Derivados de imidazol, su preparacion y su utilizacion como medicamento - Google Patents

Derivados de imidazol, su preparacion y su utilizacion como medicamento

Info

Publication number
AR044567A1
AR044567A1 ARP040101827A ARP040101827A AR044567A1 AR 044567 A1 AR044567 A1 AR 044567A1 AR P040101827 A ARP040101827 A AR P040101827A AR P040101827 A ARP040101827 A AR P040101827A AR 044567 A1 AR044567 A1 AR 044567A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
radicals
aryl
different
Prior art date
Application number
ARP040101827A
Other languages
English (en)
Inventor
Dennis Bigg
Anne-Marie Liberatore
Dominique Pons
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0306403A external-priority patent/FR2855520B1/fr
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR044567A1 publication Critical patent/AR044567A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de los imidazoles. Estos productos presentan actividad anti-tumoral. La presente concierne tanto a los compuestos farmacéuticos conteniendo tales productos como su utilización para la preparación de un medicamento anti- tumoral. Reivindicación 1: Compuesto de fórmula general (1), en su forma racémica, de enantiómeros o todas las combinaciones de estas formas y en la cual: X representa uno o varios sustituyentes idénticos o diferentes elegidos entre H y halo; Y representa -O- o -S-; A representa H o (C1-6) alquilo; Z representa uno o varios sustituyentes idénticos o diferentes elegidos entre: (C1-6) alquilo eventualmente sustituido por uno o varios radicales halo idénticos o diferentes; arilo eventualmente sustituido por uno o varios radicales idénticos o diferentes elegidos entre: halo, nitro, ciano, hidroxi, (C1-6)alquilo eventualmente sustituido por uno o varios radicales halo idénticos o diferentes, -(CH2)n-NR3R4, (C1-6) alquilsulfonilo, (C1-6) alquiltio, (C1-6) alcoxi eventualmente sustituido por uno o varios radicales halo idénticos o diferentes, (C1-6) alcoxicarbonilo, fosfato, sulfato, glicósido y NH-C(O)-CH(RA)-NR5R6; aril-(C1-6) alquilo; heteroarilo; -Z1-Z'1; -NRN-C(O)-Z'2; o Z2-Z'2; Z1 representa -O-, -C(O)-O. -NRN-C(O)-O-C(O)-NRN; Z'1 representa un radical (C1-6) alquilo; aril-(C1-6) alquilo cuyo radical arilo es eventualmente sustituido por uno o varios radicales halo idénticos o diferentes; (C1-6) alquilo sustituido por uno o varios sustituyentes elegidos entre halo, (C1-6) alcoxi, (C1-6) alquiltio y -NR1R2; R1 y R2 representan, independientemente, H o (C1-6) alquilo, o bien forman junto con el átomo de nitrógeno al cual están unidos, un heterocicloalquilo eventualmente sustituido por (C1-6) alquilo; Z2 representa -O-, -S-, SO2-, -C(O)-, -C(O)-NRN- o NRN; Z'2 representa un radical arilo o heteroarilo, los radicales arilo y heteroarilo, siendo eventualmente sustituidos por uno o varios radicales idénticos o diferentes entre: halo, nitro, ciano, hidroxi, (C1-6) alquilo eventualmente sustituido por uno o varios radicales halo idénticos o diferentes, (C1-6) alquilsulfonilo, (C1-6) alcoxi eventualmente sustituido por uno o varios radicales halo idénticos o diferentes, aril-alcoxi, (C1-6)alcoxicarbonilo, fosfato, sulfato, glicósido, -(CH2)n-NR3R4 y NH-C(O)-CH(RA)-NR5R6; R3 y R4 representan, independientemente, H, (C1-6) alquilo, (C1-6) alquilcarbonilo o (C1-6) alquilsulfonilo, o bien R3 y R4 forman junto con el átomo de nitrógeno al cual están unidos, un heteroarilo o un heterocicloalquilo eventualmente sustituido por (C1-6) alquilo; R5 y R6 representan independientemente, H o (C1-6) alquilo; RA representa el residuo asociado al aminoácido de fórmula: NH2-CH(RA)-C(O)-OH; RN representa el hidrógeno o un radical (C1-6) alquilo; n representan un entero de 0 a 3; o una sal aceptable desde el punto de vista farmacéutico de este último, excluyendo los compuestos en los cuales A representa al átomo de hidrógeno y Z al radical -3-CF3.
ARP040101827A 2003-05-27 2004-05-27 Derivados de imidazol, su preparacion y su utilizacion como medicamento AR044567A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0306403A FR2855520B1 (fr) 2003-05-27 2003-05-27 Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
FR0306712 2003-06-04

Publications (1)

Publication Number Publication Date
AR044567A1 true AR044567A1 (es) 2005-09-21

Family

ID=33492216

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101827A AR044567A1 (es) 2003-05-27 2004-05-27 Derivados de imidazol, su preparacion y su utilizacion como medicamento

Country Status (16)

Country Link
US (1) US7534805B2 (es)
EP (1) EP1638943B1 (es)
JP (1) JP2007501267A (es)
KR (1) KR101109948B1 (es)
CN (1) CN1795179A (es)
AR (1) AR044567A1 (es)
AT (1) ATE403649T1 (es)
BR (1) BRPI0410623A (es)
CA (1) CA2527192C (es)
DE (1) DE602004015600D1 (es)
EA (1) EA010392B1 (es)
ES (1) ES2311847T3 (es)
HK (1) HK1089671A1 (es)
MX (1) MXPA05012679A (es)
PT (1) PT1638943E (es)
WO (1) WO2004106307A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
CA2613517A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
CA2641734A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
FR2900404B1 (fr) * 2006-04-27 2008-07-18 Sod Conseils Rech Applic Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
US8414534B2 (en) * 2006-11-09 2013-04-09 Abbott Medical Optics Inc. Holding tank devices, systems, and methods for surgical fluidics cassette
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
CA2761934C (en) * 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
EP2558446B1 (en) * 2010-04-16 2019-06-12 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US20130289047A1 (en) * 2010-10-14 2013-10-31 Epiomed Therapeutics, Inc. Heteroarylthio derivatives and analogues
UA124026C2 (uk) * 2017-01-06 2021-07-07 Рівус Фармасьютікалс, Інк. Фенільні похідні

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
PL356485A1 (en) * 1999-12-16 2004-06-28 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists

Also Published As

Publication number Publication date
PT1638943E (pt) 2008-11-14
AU2004242820A1 (en) 2004-12-09
US7534805B2 (en) 2009-05-19
CA2527192C (fr) 2013-04-09
WO2004106307A3 (fr) 2005-02-03
ES2311847T3 (es) 2009-02-16
BRPI0410623A (pt) 2006-06-20
EA200501870A1 (ru) 2006-06-30
DE602004015600D1 (de) 2008-09-18
EP1638943B1 (fr) 2008-08-06
JP2007501267A (ja) 2007-01-25
ATE403649T1 (de) 2008-08-15
WO2004106307A2 (fr) 2004-12-09
KR101109948B1 (ko) 2012-03-20
CN1795179A (zh) 2006-06-28
KR20060015301A (ko) 2006-02-16
EA010392B1 (ru) 2008-08-29
EP1638943A2 (fr) 2006-03-29
US20070066542A1 (en) 2007-03-22
CA2527192A1 (fr) 2004-12-09
HK1089671A1 (en) 2006-12-08
MXPA05012679A (es) 2006-02-08

Similar Documents

Publication Publication Date Title
AR044567A1 (es) Derivados de imidazol, su preparacion y su utilizacion como medicamento
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR051754A1 (es) Metodos para preparar compuestos de indazol
WO2013001310A1 (en) Macrocyclic compounds and their use as cdk8 inhibitors
PE20060380A1 (es) Derivados de pirido-pirimidina en la prevencion y tratamiento de la proliferacion celular
MY148636A (en) Benzimidazole derivatives
HK1089659A1 (en) Bicyclic inhibitors of mek and methods of synthesis thereof
IL289165B1 (en) Modified azole-dione compounds and pharmaceutical preparations containing them
HK1088845A1 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
EP1637521A4 (en) NEW TRICYCLIC HETEROCYCLIC COMPOUND
DK1723138T3 (da) Substituerede benzimidazoler og deres anvendelse til at inducere apoptose
EP1839662A4 (en) ANTITUMOR AGENT
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MX2009004337A (es) Compuestos lipidos omega-3.
DK2061452T3 (da) Anvendelse af koffeinsyre og derivater deraf mod cancer
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
AR050956A1 (es) Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1.
MX2009002998A (es) Derivado de pirazolopirimidina.
MXPA04008303A (es) Inhibidores de la farnesil proteina transferasa como agentes antitumorales.
DK268289A (da) Cephemforbindelser og fremgangsmaade til fremstilling deraf
BR0113675A (pt) Compostos de anti-tumor tricìclicos sendo inibidores de proteìna farnesil transferase
ES2236935T3 (es) Derivados de amidino-camptotecina.
WO2012007619A1 (es) Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal